Glasgow-based biopharmaceuticals company Aurum Biosciences has appointed a new chief executive as it looks to expand its global presence.
A 2015 clinical stage spin-out company of InnoScot Health, NHS Greater Glasgow and Clyde, and the University of Glasgow, the business develops therapeutics and diagnostics in areas of unmet clinical need.
Its patented ABL-101 platform technology represents one of the first advancements in the management of acute stroke patients in the past 20 years. It not only delivers oxygen to brain tissue under stress beyond the clot, but provides acute stroke diagnostics and helping to identify salvageable brain tissue.
